• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Q32 Bio Inc.

    4/30/26 7:08:09 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTTB alert in real time by email
    DEFA14A 1 qttb_2026_defa_14a_revis.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐

     

    Preliminary Proxy Statement

     

     

     

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

     

    ☐

     

    Definitive Proxy Statement

     

     

     

    ☒

     

    Definitive Additional Materials

     

     

     

    ☐

     

    Soliciting Material Pursuant to §240.14a-12

     

     

    Q32 Bio Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

     

    No fee required

     

     

     

    ☐

     

    Fee paid previously with preliminary materials

     

     

     

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     


     

    img34142232_0.jpg

    Your Vote Counts! Q32 BIO INC 2026 Annual Meeting Vote by June 11, 2026 11:59 PM ET Q32 BIO INC. 830 WINTER STREET WALTHAM, MA 02451 V92532-P42416 You invested in Q32 BIO INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 12, 2026 8:30 AM Eastern Time Virtually at: www.virtualshareholdermeeting.com/QTTB2026*Please check the meeting materials for any special requirements for meeting attendance.


    img34142232_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review the proxy materials before voting. Voting Items Board Recommends 1. To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal; Nominees: 1a. Kathleen LaPorte 1b. Jodie Morrison 1c. Arthur Tzianabos, Ph.D. 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; 3. To approve, on a non-binding, advisory basis, the compensation of our named executive officers; and 4. To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V92533-P42416


    Get the next $QTTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTTB

    DatePrice TargetRatingAnalyst
    5/18/2026Overweight
    Cantor Fitzgerald
    2/25/2026$13.00Buy
    H.C. Wainwright
    2/11/2025$22.00 → $3.00Outperform → Market Perform
    BMO Capital Markets
    2/11/2025$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    12/11/2024Buy → Neutral
    Guggenheim
    12/11/2024$95.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$90.00 → $22.00Strong Buy → Outperform
    Raymond James
    12/11/2024$68.00 → $9.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $QTTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:15:32 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:13:02 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Q32 Bio

    Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight

    5/18/26 8:36:12 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Q32 Bio with a new price target

    H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00

    2/25/26 7:53:48 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

    2/11/25 7:55:03 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.

    SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)

    6/1/26 9:10:34 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.

    SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)

    5/28/26 4:28:47 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Q32 Bio Inc. (0001661998) (Filer)

    5/27/26 4:01:51 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:15:32 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:13:02 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Violette Shelia M.

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    3/20/26 7:00:05 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q32 Bio Announces $55 Million Private Placement Financing

    WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million.In this private placement, the Company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares (the "Shares") of the Company's common stock, $0.0001 par

    5/27/26 8:00:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

    -- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 ---- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) ---- Completed $10.5 million registered direct offering (RDO) ---- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 --WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innov

    5/5/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

    4/8/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Financials

    Live finance-specific insights

    View All

    Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

    4/8/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

    2/18/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    11/14/24 5:46:10 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Q32 Bio Inc.

    SC 13G - Q32 Bio Inc. (0001661998) (Subject)

    11/13/24 4:05:13 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    10/25/24 6:06:25 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care